







FIG. 2




FIG. 3C




FIG. 3D

EC50s (µg/mL)									
	clone 2	clone 5	clone 13	clone 16	clone 17	clone 20	clone 25	clone 54	
human	0.15	0.12	0.07	0.07	0.06	0.24	0.14	0.11	
mouse	0.25	5.39	0.08	0.08			0.24		
cyno	0.32	1.17	0.10	0.10			0.19	11.44	

FIG. 4




FIG. 5B




FIG. 5A




FIG. 6




FIG. 7A
Anti-TIGIT Antibody-Mediated Luciferase Induction





FIG. 7B




FIG. 8




FIG. 9B




FIG. 9A




FIG. 9C




FIG. 9D

EC50s (µg/mL)

	c13 hlgG1	c13 mlgG1	c13 mlgG2a
human	0.09	0.05	0.04
mouse	0.10	0.06	0.05
cyno	0.13	0.07	0.07

FIG. 9F




FIG. 9E




FIG. 9G




FIG. 9H





FIG. 10A

aTIGIT + aPD-1 Tumor Efficacy in CT26 Syngeneic Model
Group Mean Tumor Volume



Balb/c female mice

CT26 (3E+05 cells/mouse) s.c. inoculation 28Oct2016

aTIGIT: biwk x 3 IP dosing from day 1

13-1 = mlgG1 chimera of clone 13

13-2 = mlgG2a chimera of clone 13

aPD-1: biwk x 2 IP dosing from day 1

Study day 1 = day 7 after tumor inoculation

Charles River Laboratories Study # CT26-e323

FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F




FIG. 10G




FIG. 10H




FIG. 10I




FIG. 10J





FIG. 10K







FIG. 11



	mIgG2a	mIgG2a AFUCOS.	mIgG2a LALA-PG
KD (nM)	33.4	2.37	3330
KD Std. Error	1.1	0.21	120
Bmax	16720	19270	17045

FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17

FIG. 18A




FIG. 18B





FIG. 18C






FIG. 19




FIG. 20

CMV Induced IFN γ Production




FIG. 21

Mixed Lymphocyte Reaction IL2 Production




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26A




FIG. 26B




FIG. 27




FIG.28

FIG. 29A




FIG. 29B





FIG. 29C






FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38B




FIG. 38A




FIG. 39A




FIG. 39B




FIG. 39C




FIG. 39D




FIG. 40




FIG. 41